Please login to the form below

Not currently logged in
Email:
Password:

Frances Heller joins BMS senior management

Takes up business development role and will report to Lamberto Andreotti

Bristol-Myers Squibb has appointed Frances Heller as senior vice president, business development.

Reporting to the pharma company's CEO Lamberto Andreotti, she will also sit on the BMS senior management team.

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

Prior to that she served as head of strategic alliances at Novartis and before that as corporate and intellectual property counsel for Celera Genomics.

“With broad experience across both the biotech and pharmaceutical industries, I believe Fran will be an important addition to my diverse management team and to the company,” said Andreotti.

“In addition, her scientific, business and legal background, as well as her experience across therapeutic areas, will help Bristol-Myers Squibb continue to execute its strategy of finding external innovation that complements our own internal R&D pipeline and helps us bring important new medicines to patients.”

2nd October 2012

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

OUTiCO Case Study - Product Launch
POSITIVE FORMULARY SUCCESS WITHIN 8 MONTHS!...
An insight into Multi-Channel Account Management
At OUTiCO we often talk about moving away from traditional methods, embracing change, and offering an exceptional outsourcing service, but what does that mean day to day?...
14_ipad_lowres.jpg
Why AI might be the rep’s best friend
When looking for the next big thing in digital communication, there’s nothing bigger than the sweeping changes promised by artificial intelligence. There’s little doubt that AI is coming to pharma...

Infographics